Postbiotica | A new article of the Lab. Mucosal Immunology and Microbiota will be published: “The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage”.
POSTBIOTICA is an innovative Biopharmaceutical Company born to develop a new therapeutic treatments based on new molecules with a high biological impact called POSTBIOTICS. We hold a new fermentative process in which we design e modulate the Postbiotics productions.
postbiotica, postbiotics, postbiotics productions, biopharmaceutical company
17251
post-template-default,single,single-post,postid-17251,single-format-link,ajax_fade,page_not_loaded,,qode-theme-ver-16.7,qode-theme-bridge,wpb-js-composer js-comp-ver-5.5.2,vc_responsive
 

A new article of the Lab. Mucosal Immunology and Microbiota will be published: “The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage”.

The work of the Mucosal and Microbiota Immunology Laboratory directed by Prof. Maria Rescigno at Humanitas Research Hospital will be published in The Journal Of Urology.

The dogma that urine is sterile has been overturned and dysbiosis of the urinary microbiome has been linked to many urological disorders. We tested the hypothesis that the urinary microbial composition may be different between men with or without bladder cancer in catheter-collected urines, bladder washouts and midstream voided urines, and may be dependent on tumor staging.

The results of the work led to find that the bladder is colonized by endogenous bacteria and microbial modifications characterize the microbiome of bladder cancer patients. Different microbial compositions can be characterized by changing sampling strategy. These results pave the way for exploring new diagnostic and therapeutic options based on the manipulation of the bacterial community.

https://www.auajournals.org/doi/10.1097/JU.0000000000001336

No Comments

Post A Comment